Zealand Pharma AS (STU:22Z) Shares Outstanding (Basic Average): 71 Mil (As of Mar. 2026)


STU:22Z Zealand Pharma AS STU:22Z
52 GF Score
Price €38.10
GF Value €1,732.21
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Shares Outstanding (Basic Average)?

Zealand Pharma AS STU:22Z +0.71% 52 Shares Outstanding (Basic Average) is 71 Mil as of Mar. 2026. GuruFocus rates STU:22Z with a GF Score™ of 52/100 and a GF Value™ of €1,732.21 (Possible Value Trap). The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Zealand Pharma AS's average basic shares outstanding for the quarter that ended in Mar. 2026 was 71 Mil.


Zealand Pharma AS  (STU:22Z) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Zealand Pharma AS Shares Outstanding (Basic Average) Related Terms


Zealand Pharma AS Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Shares Outstanding (Basic Average) Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.87 46.20 56.59 66.43 70.50

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.68 70.73 70.30 70.35 70.61
STU:22Z
52GF Score
Zealand Pharma AS STU:22Z
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 71 Mil mean?
Zealand Pharma AS (STU:22Z) has a Shares Outstanding (Basic Average) of 71 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Shares Outstanding (Basic Average) too high?
Zealand Pharma AS's current Shares Outstanding (Basic Average) is 71 Mil. Overall, Zealand Pharma AS has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Shares Outstanding (Basic Average) compare to VRTX and REGN?
Zealand Pharma AS's Shares Outstanding (Basic Average) of 71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Shares Outstanding (Basic Average) is 71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (STU:22Z) is currently considered Possible Value Trap. The stock's GF Value™ is €1,732.21, compared to a current price of €38.10 — trading 97.8% below its estimated fair value. The current Shares Outstanding (Basic Average) is 71 Mil. Zealand Pharma AS's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Zealand Pharma AS (STU:22Z), the current Shares Outstanding (Basic Average) is 71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (STU:22Z) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of €38.10 is trading 97.8% below its estimated GF Value™ of €1,732.21. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for STU:22Z:

  • Shares Outstanding (Basic Average): 71 Mil
  • GF Value™: €1,732.21 vs. price of €38.10 (97.8% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the STU:22Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
52GF Score

Get the complete analysis for STU:22Z

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.10
Price
€1,732.21
GF Value